# Povofortay (povorcitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/povorcitinib

> The next catalyst for Povofortay (povorcitinib), sponsored by INCYTE CORP (INCY), is its primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Povofortay (povorcitinib) |
| Codes | INCB054707, INCB54707 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | moderate to severe uncontrolled asthma, moderate to severe uncontrolled asthma and in chronic spontaneous urticaria, [asthma](https://sec-api.dev/indications/asthma), [chronic spontaneous urticaria](https://sec-api.dev/indications/chronic-spontaneous-urticaria), [Hidradenitis Suppurativa (HS)](https://sec-api.dev/indications/hidradenitis-suppurativa-hs), [NonSegmental Vitiligo](https://sec-api.dev/indications/nonsegmental-vitiligo), [Prurigo Nodularis](https://sec-api.dev/indications/prurigo-nodularis), [Moderate to Severe Asthma](https://sec-api.dev/indications/moderate-to-severe-asthma) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Dec 2022: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-02-10, last confirmed 2025-07-29.
- SEC Form 10-Q (accession 0000879169-25-000103): "In December 2022, we initiated two Phase 3 trials (STOP-HS1 and STOP-HS2) in moderate to severe HS." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In December 2022, we initiated two Phase 3 trials (STOP-HS1 and STOP-HS2) in moderate to severe HS." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In December 2022, we initiated two Phase 3 trials (STOP-HS1 and STOP-HS2) in moderate to severe HS." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: moderate to severe uncontrolled asthma.
- First seen 2025-02-10, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0000879169-26-000066): "In July 2023, we initiated a Phase 2 study evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm
- SEC Form 10-Q (accession 0000879169-26-000056): "In July 2023, we initiated a Phase 2 study evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm
- SEC Form 10-Q (accession 0000879169-26-000026): "In July 2023, we initiated a Phase 2 study evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "In July 2023, we initiated a Phase 2 study evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- SEC Form 10-Q (accession 0000879169-25-000118): "In July 2023, we initiated a Phase 2 trial evaluating povorcitinib in patients with moderate to severe uncontrolled asthma." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "In July 2023, we initiated two Phase 2 trials evaluating povorcitinib in patients with moderate to severe uncontrolled asthma and in chronic spontaneous urticaria." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In July 2023, we initiated two Phase 2 trials evaluating povorcitinib in patients with moderate to severe uncontrolled asthma and in chronic spontaneous urticaria." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In July 2023, we initiated two Phase 2 trials evaluating povorcitinib in patients with moderate to severe uncontrolled asthma and in chronic spontaneous urticaria." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Apr 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: chronic spontaneous urticaria.
- First seen 2025-07-29, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0000879169-25-000118): "In April 2025, we announced positive topline results from the Phase 2 study evaluating povorcitinib in patients with CSU." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "In April 2025, we announced positive topline results from the Phase 2 study evaluating povorcitinib in patients with chronic spontaneous urticaria." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm

### early 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-07-29, last confirmed 2025-07-29.
- Press release filed with the SEC (EX-99) (accession 0000879169-25-000100): "the potential blockbuster opportunity presented by povorcitinib and plans to develop same, including the submission of an NDA in early 2026" https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm

### Q1 2026: NDA/BLA acceptance

- Status: scheduled. Date confidence: quarter.
- First seen 2026-02-10, last confirmed 2026-02-10.
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000006): "The acceptance by the FDA of our New Drug Application (NDA) submission for povorcitinib in HS is anticipated in the first quarter of 2026, with potential approval by early 2027." https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm
- SEC Form 10-K (accession 0000879169-26-000010): "The acceptance by the FDA of our NDA submission for povorcitinib in HS is anticipated in the first quarter of 2026, with potential approval by early 2027." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm

### February 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: NonSegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06113445

### March 17, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: NonSegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06113471 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06113471

### September 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06516965

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06516965

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06516952

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Prurigo Nodularis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06516952

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Moderate to Severe Asthma.
- First seen 2026-02-10, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT05851443
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000063): "•Topline data from the Phase 2 proof-of-concept trial for povorcitinib in patients with asthma are anticipated by year-end 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000053): "•Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000023): "▪Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-q12026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000006): "▪Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Moderate to Severe Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT05851443

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06212999

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06212999

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06855498

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06855498

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT07213973

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hidradenitis Suppurativa (HS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT07213973

## Same indication

- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Dupixent (dupilumab)](https://sec-api.dev/pdufa/dupilumab) (REGN)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [SL-325](https://sec-api.dev/pdufa/sl-325) (STTK)
- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib) (CRVS)
- [SPY072](https://sec-api.dev/pdufa/spy072) (SYRE)
- [APPROACH (tibulizumab)](https://sec-api.dev/pdufa/tibulizumab) (ZURA)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/povorcitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Povofortay (povorcitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/povorcitinib

```bibtex
@misc{secapidev_pdufa_povorcitinib_20261116,
  title        = {Povofortay (povorcitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/povorcitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_povorcitinib_20261116","title":"Povofortay (povorcitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/povorcitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
